4.5 Article

Which Analysis Approach Is Adequate to Leverage Clinical Microdialysis Data? A Quantitative Comparison to Investigate Exposure and Reponse Exemplified by Levofloxacin

Journal

PHARMACEUTICAL RESEARCH
Volume 38, Issue 3, Pages 381-395

Publisher

SPRINGER/PLENUM PUBLISHERS
DOI: 10.1007/s11095-021-02994-1

Keywords

levofloxacin; microdialysis; noncompartmental analysis; nonlinear mixed-effects modelling; probability of target-attainment

Funding

  1. AbbVie Deutschland GmbH Co. KG
  2. AstraZeneca GmbH
  3. Boehringer Ingelheim Pharma GmbH Co. KG
  4. Grunenthal GmbH
  5. F. Hoffmann-La Roche Ltd.
  6. Merck KGaA
  7. SANOFI

Ask authors/readers for more resources

The study systematically compared analysis methods of clinical microdialysis data to assess their impact on target-site drug exposure and response. The results showed that using the integral-CA method was most appropriate for characterizing clinical pharmacokinetics- and microdialysis-related variability, which will improve the understanding of drug target-site pharmacokinetics for therapeutic decision-making.
Purpose Systematic comparison of analysis methods of clinical microdialysis data for impact on target-site drug exposure and response. Methods 39 individuals received a 500 mg levofloxacin short-term infusion followed by 24-h dense sampling in plasma and microdialysate collection in interstitial space fluid (ISF). ISF concentrations were leveraged using non-compartmental (NCA) and compartmental analysis (CA) via (ii) relative recovery correction at midpoint of the collection interval (midpoint-NCA, midpoint-CA) and (ii) dialysate-based integrals of time (integral-CA). Exposure and adequacy of community-acquired pneumonia (CAP) therapy via pharmacokinetic/pharmacodynamic target-attainment (PTA) analysis were compared between approaches. Results Individual AUC(ISF) estimates strongly varied for midpoint-NCA and midpoint-CA (>= 52.3%CV) versus integral-CA (<= 32.9%CV) owing to separation of variability in PK parameters (midpoint-CA = 46.5%-143%CVPK, integral-CA = 26.4%-72.6%CVPK) from recovery-related variability only in integral-CA (41.0%-50.3%CVrecovery). This also led to increased variability of AUC(plasma) for midpoint-CA (56.0%CV) versus midpoint-NCA and integral-CA (<= 33.0%CV), and inaccuracy of predictive model performance of midpoint-CA in plasma (visual predictive check). PTA analysis translated into 33% of evaluated patient cases being at risk of incorrectly rejecting recommended dosing regimens at CAP-related epidemiological cut-off values. Conclusions Integral-CA proved most appropriate to characterise clinical pharmacokinetics- and microdialysis-related variability. Employing this knowledge will improve the understanding of drug target-site PK for therapeutic decision-making.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available